Hans Rickli St.Gallen
Transcript of Hans Rickli St.Gallen
![Page 1: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/1.jpg)
Update interventional Cardiology 2012
Hans Rickli
St.Gallen
![Page 2: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/2.jpg)
Review of Literature
ESC-Highlights
TCT/AHA-Highlights
26.11.2012
![Page 3: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/3.jpg)
Update interventional cardiology 2012
Structural Heart Disease
Transcatheter aortic valve replacement
Mitral valve repair
Left atrial appendage closure/ ASD and PFO-Closure
New Guidelines
Elective Percutaneous Coronary Intervention
Appropriateness
Same-day discharge
Periprocedural myocardial infarction
Left main disease
Multivessel disease and Diabetes
Medical therapy
Radial access
Bifurcation
Stent thrombosis
Contrast-induced nephropathy
26.11.2012
![Page 4: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/4.jpg)
Update interventional cardiology 2012
Drug-Eluting Stents
DES thrombosis
Second generation DES
New polymers and coatings
Acute Coronary Syndromes
ACS Registries
New Guidelines
ACS Trilogy, WOEST
Pharmacotherapy
Clopidogrel. DUAL-ANTIPLATELET THERAPY
Bleeding
Transfer
Prasugrel, Ticagrelor
26.11.2012
![Page 5: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/5.jpg)
Two-Year Outcomes after Transcatheter
or Surgical Aortic-Valve Replacement
N Engl J Med 2012;366:1686-95.
![Page 6: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/6.jpg)
Two-Year Outcomes after Transcatheter
or Surgical Aortic-Valve Replacement
N Engl J Med 2012;366:1686-95.
two treatments were similar with respect to
Mortality
reduction in symptoms
improved valve hemodynamics,
![Page 7: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/7.jpg)
Two-Year Outcomes after Transcatheter
or Surgical Aortic-Valve Replacement
N Engl J Med 2012;366:1686-95.
Paravalvular
regurgitation more
frequent after TAVR
associated with
increased late
mortality.
![Page 8: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/8.jpg)
Transcatheter aortic valve replacement
Transcatheter aortic valve implantation: the evidence.
Heart 2012: Nov; 98 Suppl 4
(1) standard-of-care for inoperable patients with better
outcome than conservative management
(2) In high-risk patients, TAVI has clearly shown non-
inferiority compared with surgical aortic valve
replacement
(3) Despite encouraging results from national registries, the
use of TAVI in intermediate-risk patients has no evidence
so far
(4) Technological advances promise to simplify TAVI to
improve outcome by reducing rate of TAVI-specific issues
Stroke
peri-prosthetic aortic regurgitation
acute kidney injury
vascular complications and conduction disturbances
![Page 9: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/9.jpg)
Update interventional cardiology 2012
![Page 10: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/10.jpg)
Access Europe Registry
W.Schillinger, ESC 2012
![Page 11: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/11.jpg)
Access Europe Registry
W.Schillinger, ESC 2012
![Page 12: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/12.jpg)
Echocardiographic and Clinical Outcome
W.Schillinger, ESC 2012
![Page 13: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/13.jpg)
Mitral-Clipping: Acute and 12-month results with catheter-
based mitral valve leaflet repair: the EVEREST II J Am Coll Cardiol 2012;59:130–9
MR Reduction Through Discharge
![Page 14: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/14.jpg)
Mitral-Clipping: Acute and 12-month results with catheter-
based mitral valve leaflet repair: the EVEREST II J Am Coll Cardiol 2012;59:130–9
Left Ventricular End-Diastolic and End-Systolic Volumes
![Page 15: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/15.jpg)
Mitral-Clipping: Acute and 12-month results with catheter-
based mitral valve leaflet repair: the EVEREST II J Am Coll Cardiol 2012;59:130–9
Kaplan-Meier Curve for Survival: All Patients
![Page 16: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/16.jpg)
ESC Guidelines 2012 European Heart Journal (2012) 33, 2475
The percutaneous mitral clip procedure
(1) may be considered in patients with
symptomatic severe secondary MR despite
optimal medical therapy (including CRT if
indicated)
(2) who fulfil the echo criteria of eligibility
(3) are judged inoperable or at high surgical risk by
a team of cardiologists and cardiac surgeons,
and
(4) who have a life expectancy greater than 1 year
(recommendation class IIb,level of evidence C).
![Page 17: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/17.jpg)
Elective Percutaneous Coronary Intervention
Percutaneous coronary intervention with or without on-site
coronary artery bypass surgery: A systematic review and
meta-analysis: International Journal of Cardiology 2012
![Page 18: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/18.jpg)
Percutaneous coronary intervention with or without on-site
coronary artery bypass surgery: A systematic review and meta-
analysis: International Journal of Cardiology 2012
Both primary and elective PCI can safely be
performed at NSOS centers without an increase
inmortality PCI related complications.
guidelines should reflect the lack of benefit
conferred by on-site surgical backup.
In establishing PCI programs,
adequate operator/center volumes,
patient selection, and
geographic/population considerations
…..should take precedence rather than the availability of
on-site surgical backup during PCI
![Page 19: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/19.jpg)
CLOSURE I: Closure or Medical Therapy for
Cryptogenic Stroke with Patent Foramen Ovale
Conclusion: Percutaneous device closure lacks superiority over medical therapy alone in preventing recurrent stroke and mortality in patients with paradoxical embolism and PFO.
Prospective, randomized trial enrolled 909 patients with PFO and cryptogenic stroke or TIA at 87 US and Canadian sites.
Furlan AJ, et al. N Engl J Med.
2012;366:991-999.
2-Year Follow-up Closure (n = 447)
Medical
Therapy (n = 462)
P Value
Primary Endpoint* 5.5% 6.8% 0.37
Stroke 2.9% 3.1% 0.79
TIA 3.1% 4.1% 0.44
*Stroke or TIA at 2 yrs, death at 30 days, or neurologic death 31 days to 2 yrs.
![Page 20: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/20.jpg)
RANDOMIZED EVALUATION OF RECURRENT STROKE
COMPARING PFO CLOSURE TO ESTABLISHED CURRENT
STANDARD OF CARE TREATMENT
JOHN D. CARROLL, MD, JEFFREY L. SAVER, MD, DAVID E. THALER, MD, PHD,
RICHARD W. SMALLING, MD, PHD, SCOTT BERRY, PHD, LEE A. MACDONALD, MD,
DAVID S. MARKS, MD, MBA, DAVID L. TIRSCHWELL, MD
FOR THE RESPECT INVESTIGATORS
The Final Results with Primary End Point Analyses
![Page 21: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/21.jpg)
Design Multicenter: 69 Sites (62 US, 7 Canada)
Prospective, 1:1 Randomized stratified by site and atrial septal
aneurysm
Device Group (Test):
Closure with the AMPLATZER™ PFO Occluder plus
medical therapy
Medical Group (Control): 5 Medical Treatment Regimens:
Sample Size: Event-driven – continued enrollment until 25th
endpoint
Primary Analyses
Four protocol-specified analyses with raw count primary analysis
Trial Status Trial was conducted under an Investigational Device Exemption (IDE)
Sponsor St. Jude Medical, St. Paul, MN
*Study initiated under AGA Medical, Plymouth, MN
Aspirin
Warfarin
Clopidogrel
Aspirin with dipyridamole
Aspirin with clopidogrel1
1. Aspirin with clopidogrel was removed from the protocol in 2006 based on changes to the AHA/ASA treatment guidelines
Trial Design
![Page 22: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/22.jpg)
Primary Endpoint Analysis – ITT Cohort 50.8% risk reduction of stroke in favor of device
1. Cox model used for analysis
3/9 device group patients did not have a device at time of
endpoint stroke
![Page 23: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/23.jpg)
Subpopulation Differential Treatment Effect
![Page 24: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/24.jpg)
Conclusion
For carefully selected patients with history of cryptogenic stroke and
PFO, the RESPECT Trial provides evidence of benefit in stroke risk
reduction from closure with the AMPLATZER PFO Occluder over
medical management alone
Primary analysis of ITT cohort was not statistically significant but trended
towards superiority while secondary analyses suggested superiority
Stroke risk reduction was observed across the totality of analyses with rates
ranging from 46.6% - 72.7%
PFO closure with the AMPLATZER PFO Occluder exposes patients to a
very low risk of device- or procedure-related complications
Results of the RESPECT Trial have substantial import for the treatment
of patients with a history of cryptogenic stroke and PFO
Follow-up of patients is on-going and will continue to provide additional
longer term information regarding benefits, risks, and differential
treatment effects in sub-populations
![Page 25: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/25.jpg)
Structural Heart Disease
Transcatheter aortic valve replacement
Mitral valve repair
Left atrial appendage closure/ ASD and PFO-Closure
New Guidelines
Elective Percutaneous Coronary Intervention
Appropriateness
Same-day discharge
Periprocedural myocardial infarction
Left main disease
Multivessel disease and Diabetes
Medical therapy
Radial access
Bifurcation
Stent thrombosis
Contrast-induced nephropathy
26.11.2012
![Page 26: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/26.jpg)
Elective Percutaneous Coronary Intervention
Percutaneous coronary intervention with or without on-site
coronary artery bypass surgery: A systematic review and
meta-analysis: International Journal of Cardiology 2012
![Page 27: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/27.jpg)
Percutaneous coronary intervention with or without on-site
coronary artery bypass surgery: A systematic review and meta-
analysis: International Journal of Cardiology 2012
Both primary and elective PCI can safely be
performed at NSOS centers without an increase
inmortality PCI related complications.
guidelines should reflect the lack of benefit
conferred by on-site surgical backup.
In establishing PCI programs,
adequate operator/center volumes,
patient selection, and
geographic/population considerations
…..should take precedence rather than the availability of
on-site surgical backup during PCI
![Page 28: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/28.jpg)
NEJM 2012 epub November 4th
![Page 29: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/29.jpg)
Background
• Controversy regarding superiory of CABG vs.
PCI in patients with multivessel disease and
diabetes (BARI, CARDia, SYNTAX)
• Guidelines recommend CABG
• However: no adequately powered study
available in the current treatment era (drug-
eluting stents etc.)
![Page 30: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/30.jpg)
Aim
• Aim of the Future REvascularization Evaluation
in patients with Diabetes mellitus: Optimal
managment of Multivessel disease (FREEDOM)
trial:
To determine whether CABG or PCI with DES
is the superior approach to revascularization in
patients with diabetes and multivessel coronary
artery disease
![Page 31: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/31.jpg)
Methods
• Patients with DM and multivessel disease – ≥70% stenosis in ≥2 major epicardial vessels
– ≥2 separate coronary artery territories
– No left main disease
– amenable to PCI or CABG (heart team discussion)
• Randomization CABG with arterial grafts vs. PCI with DES* (one or several sessions) and abx and dual antiplatelet therapy for ≥12 months
• Optimal secondary prevention
• * Sirolimus-eluting and paclitaxel-eluting stents, which were provided to the patients free of charge, were the predominant types of drug-eluting stents that were used in the trial
![Page 32: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/32.jpg)
![Page 33: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/33.jpg)
![Page 34: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/34.jpg)
![Page 35: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/35.jpg)
![Page 36: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/36.jpg)
Results: outcomes
![Page 37: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/37.jpg)
![Page 38: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/38.jpg)
Conclusion
(1) CABG was superior to PCI with drug-
eluting stents in patients with diabetes
and advanced (predominantly
threevessel) coronary artery disease in
that
CABG significantly reduced rates of death
and myocardial infarction
with a higher rate of stroke
![Page 39: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/39.jpg)
Drug-Eluting Stents
DES thrombosis
Second generation DES
New polymers and coatings
Acute Coronary Syndromes
ACS Registries; Shock II trial
New Guidelines
ACS Trilogy, WOEST
Pharmacotherapy
Clopidogrel. DUAL-ANTIPLATELET THERAPY
Bleeding
Transfer
Prasugrel, Ticagrelor
Renal denervation
26.11.2012
![Page 40: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/40.jpg)
FAST MI Registry
Danchin N, ESC 2012
![Page 41: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/41.jpg)
FAST MI Registry
Danchin, ESC 2012
![Page 42: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/42.jpg)
Change in patient behavior after PPCI
N.Danchin, ESC 2012
![Page 43: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/43.jpg)
Reperfusion therapy in STEMI patients over time
N.Danchin, ESC 2012
![Page 44: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/44.jpg)
30-day mortality after PPCI
N.Danchin, ESC 2012
![Page 45: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/45.jpg)
IABP Shock II trial
H. Thiele, ESC 2012
![Page 46: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/46.jpg)
Results: Mortality @ 30 days
H. Thiele, ESC
![Page 47: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/47.jpg)
Summary PPCI in STEMI
![Page 48: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/48.jpg)
ACS 2012
New ESC Guidelines
Trilogy ACS
WOEST trial
![Page 49: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/49.jpg)
ACS 2012
![Page 50: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/50.jpg)
ACS 2012
![Page 51: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/51.jpg)
Trilogy ACS
All patients on ASS 100mg;
patients < 60kg, > 75 yrs→ 5 mg Prasugrel
![Page 52: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/52.jpg)
Trilogy ACS Primary Endpoint
Roe M.T., ESC
![Page 53: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/53.jpg)
WOEST Study design
De Wilde, ESC
![Page 54: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/54.jpg)
WOEST primary Endpoint bleeding
De Wilde, ESC
![Page 55: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/55.jpg)
WOEST Secondary endpoints
De Wilde, ESC
![Page 56: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/56.jpg)
MI= any myocardial infarction
TVR=target vessel revascularization (PCI + CABG)
ST= Stent thrombosis
WOEST Secondary endpoints
De Wilde, ESC
![Page 57: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/57.jpg)
WOEST all cause mortality
De Wilde, ESC
![Page 58: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/58.jpg)
ACS 2012: Summary
![Page 59: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/59.jpg)
Renal denveration in hypertension Catheter-based renal sympathetic denervation in pts with resistent
hypertension: 18 mths follow of the Symplicity HTN-II Trial
![Page 60: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/60.jpg)
Renal denveration in hypertension Catheter-based renal sympathetic denervation in pts with resistent
hypertension: 18 mths follow of the Symplicity HTN-II Trial
![Page 61: Hans Rickli St.Gallen](https://reader031.fdocuments.net/reader031/viewer/2022013005/61cd71c41dd89547a6224643/html5/thumbnails/61.jpg)
Vor lauter Wald die Bäume gefunden…….
Thank you !